Inflammasome NLRP3 activation promotes lymphoma cell proliferation and inhibits apoptosis by upregulating c-myc and BCL2 and downregulating TP53, and Bax, which in turn reduces the antitumor effect of dexamethasone (Zhao et al., 2017). Here, MYC is linked to lymphoma.